Extracellular Gd-CA: Differences in prevalence of NSF
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Extracellular Gd-CA: Differences in prevalence of NSF. / Thomsen, H.S.; Marckmann, P.; Thomsen, Henrik S.
In: European Journal of Radiology, Vol. 66, No. 2, 2008, p. 180-183.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Extracellular Gd-CA: Differences in prevalence of NSF
AU - Thomsen, H.S.
AU - Marckmann, P.
AU - Thomsen, Henrik S.
N1 - Times Cited: 1ArticleEnglishThomsen, H. SCopenhagen Univ Hosp, Dept Diagnost Radiol 54E2, Herlev Ringvej 75, DK-2730 Herlev, DenmarkCited References Count: 18304WXELSEVIER IRELAND LTDELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDCLARE
PY - 2008
Y1 - 2008
N2 - Until recently it was believed that extracellular gadolinium-based contrast agents were safe for both the kidneys and all other organs within the dose range up to 0.3 mmol/kg body weight. However, in 2006, it was demonstrated that some gadolinium-based contrast agents may trig the development of nephrogenic systemic fibrosis, a generalized fibrotic disorder, in renal failure patients. As no prospective studies can be performed we must rely on retrospective data. From those data it is obvious that the prevalence of NSF is significantly higher after the unstable agent gadodiamide than after any other gadolinium-based agent (3-7% versus 0-1% per injection) in patients with reduced renal function. Prevalence after exposure to two gadodiamide injections is as high as 36% in patients with chronic kidney disease (CKD) stage 5. No report of NSF after the most stable agents has been reported in the peer-reviewed literature documenting that there is a difference between the various agents regarding triggering NSF. (C) 2008 Elsevier Ireland Ltd. All rights reserved Udgivelsesdato: 2008/5
AB - Until recently it was believed that extracellular gadolinium-based contrast agents were safe for both the kidneys and all other organs within the dose range up to 0.3 mmol/kg body weight. However, in 2006, it was demonstrated that some gadolinium-based contrast agents may trig the development of nephrogenic systemic fibrosis, a generalized fibrotic disorder, in renal failure patients. As no prospective studies can be performed we must rely on retrospective data. From those data it is obvious that the prevalence of NSF is significantly higher after the unstable agent gadodiamide than after any other gadolinium-based agent (3-7% versus 0-1% per injection) in patients with reduced renal function. Prevalence after exposure to two gadodiamide injections is as high as 36% in patients with chronic kidney disease (CKD) stage 5. No report of NSF after the most stable agents has been reported in the peer-reviewed literature documenting that there is a difference between the various agents regarding triggering NSF. (C) 2008 Elsevier Ireland Ltd. All rights reserved Udgivelsesdato: 2008/5
M3 - Journal article
VL - 66
SP - 180
EP - 183
JO - European Journal of Radiology
JF - European Journal of Radiology
SN - 0720-048X
IS - 2
ER -
ID: 13911393